• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A step forward in cardiovascular and renal protection: advocating for finerenone's use in Pakistan.

作者信息

Aijaz Sarah, Tanvir Marriam, Shah Syed Muhammad Rehman, Tanvir Ali

机构信息

United Medical and Dental College, Karachi, 75340, Pakistan.

Khawaja Muhammad Safdar Medical College, Sialkot, 51310, Pakistan.

出版信息

Int Urol Nephrol. 2025 Apr;57(4):1349-1350. doi: 10.1007/s11255-024-04228-w. Epub 2024 Oct 4.

DOI:10.1007/s11255-024-04228-w
PMID:39367194
Abstract
摘要

相似文献

1
A step forward in cardiovascular and renal protection: advocating for finerenone's use in Pakistan.心血管和肾脏保护的一大进步：倡导在巴基斯坦使用非奈利酮。
Int Urol Nephrol. 2025 Apr;57(4):1349-1350. doi: 10.1007/s11255-024-04228-w. Epub 2024 Oct 4.
2
Finerenone's Impact on Major Adverse Cardiovascular Events in Chronic Kidney Disease and Type 2 Diabetes Mellitus: A Systematic Review.非奈利酮对慢性肾脏病和2型糖尿病患者主要不良心血管事件的影响：一项系统评价
Cureus. 2024 Aug 31;16(8):e68274. doi: 10.7759/cureus.68274. eCollection 2024 Aug.
3
A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.非奈利酮——第三代非甾体类盐皮质激素受体拮抗剂的综合综述
Front Cardiovasc Med. 2024 Sep 23;11:1476029. doi: 10.3389/fcvm.2024.1476029. eCollection 2024.
4
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.非奈利酮在慢性肾脏病合并 2 型糖尿病患者中的药代动力学和药效学：基于 FIGARO-DKD 和 FIDELIO-DKD 的研究结果。
Diabetes Obes Metab. 2024 Mar;26(3):924-936. doi: 10.1111/dom.15387. Epub 2023 Nov 30.
5
Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health-Insights from Randomized Controlled Trials.非奈利酮：第三代盐皮质激素受体拮抗剂及其对心血管健康的影响——来自随机对照试验的见解
J Clin Med. 2024 Oct 25;13(21):6398. doi: 10.3390/jcm13216398.
6
The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.新型盐皮质激素受体拮抗剂非奈利酮在慢性肾脏病中的作用：作用机制与临床进展
Clin Exp Nephrol. 2024 Feb;28(2):125-135. doi: 10.1007/s10157-023-02413-2. Epub 2023 Oct 17.
7
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.非甾体类盐皮质激素受体拮抗剂（非奈利酮）在心脏肾脏疾病中的应用
J Clin Med. 2023 Sep 29;12(19):6285. doi: 10.3390/jcm12196285.
8
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.选择性盐皮质激素受体拮抗剂非奈利酮的心血管和肾脏结局
Cardiol Ther. 2022 Sep;11(3):337-354. doi: 10.1007/s40119-022-00269-3. Epub 2022 Jun 23.
9
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.在 2 型糖尿病中，非奈利酮的心血管-肾脏保护作用及其分子机制。
Front Endocrinol (Lausanne). 2023 Feb 13;14:1125693. doi: 10.3389/fendo.2023.1125693. eCollection 2023.
10
Effect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis.非奈利酮对心血管和肾脏结局的影响：一项系统评价和荟萃分析。
Cardiovasc Drugs Ther. 2025 Jan 4. doi: 10.1007/s10557-024-07666-x.

本文引用的文献

1
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.非甾体类盐皮质激素受体拮抗剂引发的心肾保护作用是慢性肾脏病患者的新选择。
Kidney Dis (Basel). 2022 Nov 14;9(1):12-25. doi: 10.1159/000528066. eCollection 2023 Jan.
2
Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials.非奈利酮对肾脏病和/或糖尿病患者心血管事件的影响：一项随机对照试验的荟萃分析。
Int Urol Nephrol. 2023 May;55(5):1373-1381. doi: 10.1007/s11255-022-03432-w. Epub 2022 Dec 26.
3
Association of glycated albumin to hemoglobin A1c ratio with all-cause and cardiovascular mortality among US adults: A population-based cohort study.
糖化白蛋白与血红蛋白 A1c 比值与美国成年人全因和心血管死亡率的关系：一项基于人群的队列研究。
Diabetes Res Clin Pract. 2022 Nov;193:110116. doi: 10.1016/j.diabres.2022.110116. Epub 2022 Oct 12.
4
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
5
Prevalence of chronic kidney disease in South Asia: a systematic review.南亚慢性肾脏病的患病率：一项系统评价。
BMC Nephrol. 2018 Oct 23;19(1):291. doi: 10.1186/s12882-018-1072-5.
6
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.2 型糖尿病及其相关慢性肾脏病的流行情况变化。
Nat Rev Nephrol. 2016 Feb;12(2):73-81. doi: 10.1038/nrneph.2015.173. Epub 2015 Nov 10.